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The physiology and pathology of the respiratory and gastrointestinal tracts are closely related. This similarity between the
two organs may underlie why dysfunction in one organ may induce illness in the other. For example, smoking is a major
risk factor for COPD and IBD and increases the risk of developing Crohn’s disease. Probiotics have been defined as “live
microorganisms which, when administered in adequate amounts, confer health benefits on the host.” In model systems probiotics
regulate innate and inflammatory immune responses. Commonly used probiotics include lactic acid bacteria, particularly
Lactobacillus, Bifidobacterium, and Saccharomyces, and these are often used as dietary supplements to provide a health benefit
in gastrointestinal diseases including infections, inflammatory bowel disease, and colon cancer. In this respect, probiotics probably
act as immunomodulatory agents and activators of host defence pathways which suggest that they could influence disease severity
and incidence at sites distal to the gut. There is increasing evidence that orally delivered probiotics are able to regulate immune
responses in the respiratory system. This review provides an overview of the possible role of probiotics and their mechanisms of
action in the prevention and treatment of respiratory diseases.
1. Introduction
There is growing evidence as to how diet and nutrition
influence the microbiome and interact with the immune
system to ultimately improve human health, for example,
fecal bacteriotherapy, whereby the microflora of a healthy
patient is transplanted to a patient with ulcerative colitis (UC)
[1]. This suggests that the composition of the microbiome
has an important role in intestinal inflammation and that
restoration of a “healthymicrobiome” can promote remission
of disease. Probiotic bacteria are already used to treat or
prevent a wide range of human diseases, conditions, and
syndromes including antibiotic-associated diarrhea [2, 3] and
inflammatory bowel disease occurring as a consequence of
surgical treatment [4]. In addition, they have been proposed
to be of potential benefit in increasing numbers of therapeutic
areas, particularly in the prevention or treatment of many
different chronic inflammatory diseases [5]. Probiotics are
characterized as “live organisms, which when applied in
adequate amounts confer a health benefit to the host” [6, 7].
Recently, for example, probiotics have been shown to have
beneficial effects in models of neuronal inflammation and
pain. In particular, probiotics have been reported to decrease
the perception of visceral pain induced by distension or
inflammation [8, 9].
Emerging studies also indicate that dietary supplemen-
tation with probiotics could exert a wide range of beneficial
effects on humans with respect to reduced infections and
seasonal illness and in the attenuation of the perception of
symptoms and disease duration [10–12]. Despite this, many
aspects of the probiotic-host immune system crosstalk are
still unknown.
Probiotics can exert pleiotropic effects, including a pro-
tective role in the intestinal tract where they exert direct
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Table 1: Dietary supplementation with lactobacilli that have shown enhanced immune response and protection against respiratory tract
pathogen challenge.
LAB treatments Immune response Authors
The immune stimulation induced by L. rhamnosus
CRL1505 (Lr05) and L. rhamnosus CRL1506
(Lr06) on the resistance to infection with an
intestinal pathogen (Salmonella typhimurium)
and a respiratory pathogen (Streptococcus
pneumoniae)
Both strains were able to improve resistance against the intestinal
pathogen. Only Lr05 was able to induce a significant decrease in
the number of S. pneumoniae in the lung, prevent its dissemination
into the blood, and induce a significant increase inTh1 (INF-𝛾)
andTh2 (IL-6, IL-4 and IL-10) cytokine levels in the
bronchoalveolar lavages (BAL)
Salva et al. [55]
2 days before feeding of L. casei prior to pathogen
challenge
Increased rate ofclearance of P. aeruginosa from the lungs
increased phagocytic activity of alveolar macrophages, and
increased levels of IgA in BAL fluid
Alvarez et al. [56]
Prefeeding of L. casei (Shirota strain) for 4 months
prior to challenge
Reduced viral titre in nasal washings; increased NK activity of
splenocytes and nasal tract mononuclear cells; increased IFNQ and
TNFK production by mitogen-stimulated nasal lymphocytes
Hori et al. [57]
OVA-sensitized mice were orally administered
with Bifidobacterium breveM-16V, B. infantis
NumRes251, B. animalis NumRes252 and
NumRes253, Lactobacillus plantarum
waNumRes8, and L. rhamnosus NumRes6. After
challenge by OVA inhalation in the lungs, the
response to methacholine was measured
Pulmonary inflammation assessed by analyzing
BALF for the presence of inflammatory cells and
mediators
Of the panel of 6 strains, B. breveM-16V and L. plantarum
NumRes8 inhibited (1) the response to methacholine, (2) reduced
the number of eosinophils in the bronchoalveolar lavage fluid, and
(3) reduced both OVA-specific IgE and (4) OVA-specific IgG1,
whereas the other strains did not affect all these parameters
simultaneously. B. breveM-16V but not L. plantarum NumRes8
reduced interleukin 4, interleukin 5, and interleukin 10
Furthermore, B. breveM-16V but not L. plantarum NumRes8
reduced acute allergic skin reactions to OVA
Hougee et al. [58]
antimicrobial effects by competing with local pathogens and
indirectly by enhancing intestinal barrier functions [13].
In addition, probiotics have the ability to modulate the
host’s local and systemic mucosal immune systems [14].
For example, probiotics can change the mucosal immune
system towards a noninflammatory, tolerogenic pattern by
increasing IL-10 levels [15]. Moreover, the induction of
CD4+Foxp3+ regulatory (Treg) cells by probiotics inhibits the
production of proinflammatory cytokines and may skew T
cells towards a T-helper (Th) 1 phenotype [16–19].The precise
cytokine profile depends upon the nature and strength of
the stimulus and the strain of probiotic bacteria that was
administered [20, 21]. Moreover, the method of growing and
preparing probiotic bacteria for consumption can influence
their biological activity. Finally, while probiotics are applied
predominantly as living bacteria, bacterial lysates have also
been described as having immunomodulatory and anti-
inflammatory effects as well (see Table 1).
In this regard, it is important to gain a better under-
standing of the immunomodulatory mechanisms underlying
probiotic functions in order to improve the targeting of
probiotic interventions by selecting the optimal strain(s).
The fact that probiotic treatment can modulate immune
responses in the lung [22] and, in particular, the encouraging
indications that microbial stimulation of the gut can enhance
the T regulatory response in the airway [23], emphasizes
the therapeutic potential as well as the need for greater
understanding of the mechanisms underlying effects of spe-
cific probiotic strains. In this regard, identification of the
key immunoregulatory components of bacteria and/or their
metabolism and confirming that results obtained in animal
models translate into human models will be critical to the
selection of strains and treatment strategies that are most
likely to meet with success in preventing or treating human
airways diseases such as asthma and COPD.
Most probiotics contain lactic acid-producing bacteria
(LABs, e.g., Lactobacillus, Streptococcus, Bifidobacterium, and
Enterococcus sp.) or nonpathogenic yeasts such as Saccha-
romyces boulardii [24, 25]. These products are advocated for
the prevention and treatment of various medical conditions,
including gastroenteritis, Clostridium-associated diarrhea,
inflammatory bowel disease, food allergies, and dental cav-
ities. These applications of LAB have been based on various
hypothesized health-promoting attributes including antimu-
tagenic activity [26], anticarcinogenic and -tumor effects
[27–30], hypocholesterolemic properties [28], inhibition of
intestinal and food-borne pathogens [29], and the promotion
of T- and B-cell proliferation [31]. Thus, understanding the
immunological mechanism of probiotic action is important
in rationalising the impact of these agents in a variety of
diseases. Many in vitro and in vivo studies have been con-
ducted examining the effects of probiotics in disease models.
Most in vitro studies have examined the effects of probiotics
on the production of cytokines from human PBMCs in
order to define the basis for their clinical benefit [32, 33].
However, translation of these results into in vivo effects in
man in randomized controlled clinical trials will require
better models of disease and understanding of probiotic
function in order to enable the selection of optimal strains
and prediction of clinical efficacy.
The microflora hypothesis proposes that antibiotic use
and dietary differences in industrialized countries have
resulted in perturbations of the gastrointestinal micro-
biota thereby disrupting the normal microbiota-mediated
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Figure 1: The putative immunomodulatory functions of probiotics on lung disease asthma and COPD. The immune and inflammatory
drivers of allergic asthma (left side of figure) and of COPD (right side of figure) may be modified by strain-specific probiotics. The precise
mechanisms by which gut-located probiotics can cause immunomodulation in the airway are unclear but may reflect changes in blood and
local immune cells including T-cell subsets.
mechanisms of immunologic tolerance in themucosa leading
to an increase in the incidence of allergic diseases includ-
ing asthma [34]. This hypothesis provides a rationale for
the application of probiotics to aim for normalization of
immunological balance and treatment of disease. Lactobacilli
and Bifidobacteria strains are often employed as (potential)
probiotics, many of which are usefulmicroorganisms in dairy
technology with a long-documented history of use in foods.
2. Immunomodulatory Effects of Probiotics
The mechanisms by which probiotic bacteria elicit their
effects are not fully understood. The immune response
to probiotics is generally thought to be strain dependent,
with differences proposed to be due to the diverse protein
and glycan/carbohydrate profiles present in their cell walls,
the differing CpG content of their DNA, and possibly the
metabolites and other molecules they excrete [35]. The
beneficial effects of probiotics are thought to be based partly
on their ability to differentially regulate the production of
anti and proinflammatory cytokines and the balance between
types of T cell responses such as Th1/Th2, Treg, and Th17
responses [36–38] (see Figure 1).
Probiotic treatment of infectious diarrhea in both adults
and children appears efficacious, although evidence of their
effectiveness in other diseases often remains to be confirmed
in placebo-controlled randomized clinical trials [39–41]. In
diarrhea both antipathogenic mechanisms on the microbiota
level as well as immunomodulation of the host mechanisms
may underlie the clinical benefit of probiotic therapy. At
present it is unclearwhat the relative contribution of these dif-
ferentmechanisms is. Oral administration of Lactobacillimay
modulate cytokine profiles not only at the intestinal level but
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also systemically [34]. To date, several LAB strains have been
shown to enhance cell-mediated immune responses, includ-
ing T-lymphocyte proliferation, mononuclear cell phagocytic
capacity, and NK cell tumoricidal activity [42] (see Figure 1).
Additional medical applications have been proposed,
although their true efficacy will depend upon the outcomes
of future experimental and clinical studies. Indeed, despite
the widespread advocacy of the clinical benefit of probiotics,
evidence-based support for their use is limited and in need of
continuing evaluation.
Current ideas center on the hypothesis that administra-
tion of probiotic bacteria to the airwaymucosa is not required
to treat airways disease. Thus, LAB can protect host animals
from airway infection through an interaction with GALT
such as those in Peyer’s Patches in the gut eliciting an indirect
enhancement of respiratory immunity [43]. However, it has
also been proposed that the protective effects of probiotics
(both intranasal and oral) are associated with activation of
proinflammatory NK cell and/or macrophages within the
airway mucosa [43, 44]. In support of this, Koizumi et al.
[45] showed that treating mice with Lactobacillus pentosus
augmented the activity of NK cells within the spleen and
stimulatedNK1.1-positiveNKandNKTcells to produce IFN-
𝛾. The increase in IFN-𝛾 production did not occur through
direct action of Lactobacillus pentosus on NK cells but was
dependent on IL-12 produced by CD11c+ DCs following a
TLR2 and/or TLR4-dependent interaction between the DC
and LAB [32, 46]. Strains of LAB differ greatly in their ability
to induce high levels of IL-12 in humanDCs and consequently
DC-dependent IFN-𝛾 production by NK cells [47].
The effect of probiotics on other inflammatory cells has
also been described. For example, the involvement of Th17
and Treg cells in lung disease has become clear. Th17 cells are
a subset of CD4+ T cells that produce the proinflammatory
cytokine IL-17 [48]. Th17 cells have recently been shown
to play a critical role in clearing pathogens during host
defense reactions and in inducing tissue inflammation in
autoimmune disease [48]. Treg cells are considered to be the
master regulators of the immune response in both humans
and rodents. Defects in the transcription factor FoxP3, which
defines the Treg lineage, result in multiple autoimmune
diseases and atopy [49, 50] demonstrating the central role of
FoxP3+CD4 cells in immune homeostasis.
Karimi et al. have demonstrated that 9 days oral admin-
istration of Lactobacillus reuteri resulted in a significant
increase in the percentage and total number of spleen
CD4+ CD25+ FoxP3+ T cells [51]. In addition, increases
in FoxP3 mRNA expression in peribronchial lymph nodes
has been noted upon administration of Bifidobacterium lactis
Bb12, LGG, and Lactobacillus casei DN114001 suggesting the
induction of Treg cells by these strains [52]. In addition to
enhancing Treg-cell numbers, LGG has shown effects in a
number of Th2-, Th1-, andTh17-mediated disorders [53, 54].
3. Probiotics as a Therapeutic Approach in
Prevention of Lung Diseases
3.1. Asthma andAllergic Reactions. Therise in allergic disease
is becoming a major global health issue fast. Whilst this was
first evident in the more developed countries of Australasia,
Western Europe and North America where more than 40%
of the population may be affected at some stage [59, 60],
it is now becoming apparent in virtually all regions of the
world undergoing industrial development andwesternization
[61]. International trends, therefore, provide some indication
that environmental changes can affect immune function
regardless of genetic background. However, recent evidence
that non-Caucasian races may be even more susceptible
to allergic disease [62, 63] has alarming implications for
the most populous areas of the world undergoing rapid
urbanization.
Although the exact mechanism(s) behind the antiallergic
action of probiotics remain obscure, studies have high-
lighted several potential components of this response. The
development of mucosal and systemic tolerance relies on
immunosuppressive mechanisms orchestrated by Treg cells
that attenuate bothTh1 andTh2 responses, and there is accu-
mulating evidence linking the immunomodulatory function
of microbial components and/or commensal bacteria to the
induction of Treg cells and their associated cytokines.
Extensive studies examining probiotic modulation of
allergic reactions have been reported for atopic eczema with
LGG as the probiotic [63–67]. However, clinical trials of pro-
biotics in the treatment of eczema and other allergic diseases
have yielded inconsistent results [68–72]. For example, two
studies using LGG, with similar study designs, resulted in
either a decrease in eczema [73, 74] or no clinical benefit [75].
Despite the inconsistent effects seen in some studies,
several allergic diseases may be prevented with treatment of
the intestinal flora with probiotics [76, 77] and probiotics
have been proposed as being able to both prevent and
treat several allergic diseases [78]. In a murine model of
asthma, administration of Lactobacillus reuteri, LGG, and
Bifidobacterium breve decreased airway hyperresponsiveness,
the number of inflammatory cells in bronchoalveolar lavage
(BAL) fluid, and inflammation of lung tissue [58, 79].
In addition to the prevention of experimental asthma,
probiotics can prevent atopic dermatitis in infants and allevi-
ate food allergy [80–82]. Recently, Donkor et al. reported that
some probiotics induced significant amounts of proinflam-
matory cytokines, including IL-2, which is a critical cytokine
for the clonal expansion of recently antigen-activated T cells
and also in Treg homeostasis [32] (see Figure 1).
Specific bacterial strains have been shown to induce IL-
10 producing Treg cells in vitro [82]. In vivo, effects on both
regulatory and effector T cells by Lactobacillus casei DN114001
have been associated with decreased allergic skin inflamma-
tion. In addition, in vivo treatment with a preparation of heat-
killedMycobacterium vaccae can induce allergen-specific Treg
(CD4 CD45Rblo IL-10+) cells that confer protection against
allergic airway inflammation [83]. Furthermore, Feleszko
and colleagues demonstrated that early-life treatment with
LGG leads to an attenuated allergic airway response in
adult animals that is associated with an increased T cell
expression of Foxp3 [84], whereas Bifidobacterium infantis
induces Foxp3+ T cells that protect mice against Salmonella
typhimurium infection [85].
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Interestingly, oral administration of Enterococcus faecalis
FK-23 has recently been shown to suppress the asthmatic
response and that this is associated with attenuation of Th17
cell development [86].
Overall, it is unlikely that LABs directly enter into the
circulation and then into the lungs. By contrast, they are likely
to have an immunomodulatory action affecting the function
of immune cells that migrate into the lung. The precise
mechanisms underlying the favorable effects of probiotics on
the respiratory system are unclear, and several mechanisms
have been proposed as a result of in vitro and in vivo animal
experiments. In addition to modulation of the intestinal
microbiota, probiotics improve the barrier function of the
intestinal mucosa, reducing leakage of antigens through the
mucosa and thereby the amount of allergen that the lung
may be exposed to via the circulatory route. In addition,
direct modulation of the immune system may occur through
the induction of anti-inflammatory cytokines or through the
increased production of secretory IgA or via activation of
Treg cells and skewing of Th1, Th2, and Th17 cell activation
or alterations in macrophage function resulting in reduced
allergic responses. For example, Salva et al. showed that
changes in the BAL cytokine profile occurred after LAB
application and that these were associated with an increase
in the number and activity of phagocytic cells and with
increased levels of allergen-specific antibodies in serum and
BAL [55].
3.2. Viral Infections and Asthma. Respiratory infections, par-
ticularly viral infections, directly affectmorbidity andmortal-
ity and are indirectly a contributing factor not only to asthma
exacerbations but also to the development of the disease [87].
It has been speculated that identifying probiotic organisms
capable of reducing viral infections in early life, or in utero,
may prevent the development of asthma [88]. As indicated
above, emerging evidence supports the role of probiotics, for
example, LGG and Lactobacillus casei strains Shirota (LcS)
andDN114001, in the prevention and/or treatment of bacterial
and viral infections in the gastrointestinal and respiratory
systems including influenza [57, 89–93].
Respiratory pathogens are recognized by pattern recog-
nition receptors (PRRs). For example, Toll-like recep-
tors (TLRs), nucleotide-binding oligomerization domain
(NOD-) like receptors, transcription factors, cytokines, and
chemokines play essential roles in sensing perturbations in
the health of the lungs. The expression of many PRRs is high
in lung inflammatory cells such as neutrophils, monocytes,
macrophages, and epithelial cells, and they are able to respond
rapidly to increased levels of PAMPs and DAMPs which are
associated with exacerbation of lung diseases. It is possible,
therefore, thatmodulation of these responses induced by LAB
may have an impact on immune cell activation in the lung.
In addition to oral delivery of probiotics, probiotic effi-
cacy has been demonstrated following nasal challenge. Thus,
Harata et al. reported that intranasal administration of LGG
could protect mice from H1N1 influenza virus infection by
regulating respiratory immune responses [94]. In addition,
probiotic use has been associated with lower incidence of
ventilator-associated pneumonia [95], reduced respiratory
infections in healthy and hospitalized children [96, 97], and
reduced duration of infection with the common cold [98].
3.3. Chronic Obstructive Pulmonary Disease (COPD). COPD
is currently the 4th biggest killer worldwide and is expected
to be the third leading cause of death over the next 10
years [99]. Smoking is the most important lifestyle risk
factor for pathogenesis of COPD [100] and lung cancer [101].
COPD and IBD share many epidemiological and clinical
characteristics, as well as inflammatory pathologies [102–
107]. The crosstalk between the pulmonary and intestinal
mucosal in chronic inflammatory diseases such as COPD and
IBD has recently been extensively reviewed [108].
The level of inflammation in the COPD airways is a
strong correlate of disease severity in patients and is criti-
cally involved in disease development experimentally [109–
111]. Attention has traditionally centered on the roles of
macrophages and neutrophils in disease development [112].
However, lymphocytes have received increasing attention,
and reports from many laboratories have provided insight
into functions of T cells and NK cells in the pathogenesis of
COPD [113–115].
COPD has been characterized by exacerbations of
symptoms including increased dyspnea, enhanced sputum,
enhanced inflammation, and decline in lung function [116,
117]. COPD exacerbations are psychologically destructive,
since patients with exacerbations have a lower quality of
life and decreased mobility, leading to increased depression
[118]. 40%–60% of exacerbations in COPD are caused by
viral infections [119, 120], and importantly, in animal models
viral infection following cigarette smoke exposure leads
to enhanced pulmonary inflammation, increased alveolar
apoptosis, accelerated emphysema, and airway fibrosis [120].
However, the underlying cellular mechanisms responsible for
these effects remain unresolved.
It is generally accepted that the early immune response
following viral infection relies on the recognition of viral
PAMPs through the Toll-like receptors (TLRs) mainly TLR3,
TLR7, and TLR9 [121, 122]. Stimulation of these receptors
found on DCs and other inflammatory cells leads to the
activation of NK cells through production of type I IFNs, IL-
12, IL-18, and IL-15 [123–126]. NK cell activation is critically
important to the early control of viral infections and occurs
several hours to a few days following infection [127]. NK
cells were originally thought of solely as killer cells due
to their ability to directly destroy virus-infected cells [128].
More recently, however, attention has been given to the
noncytotoxic functions of NK cells [129]. Activated NK cells
produce large amounts of IFN-𝛾 [130] and NK-cell-derived
IFN-𝛾 is critical to the inflammatory processes that control
viral infections [131–133] (see Figure 1). Thus, NK cells along
with their release of mediators are considered as important
cells regulating the inflammatory response that occurs during
COPD exacerbations.
Cigarette smoking impairs human NK-cell cytotoxic
activity and cytokine release [134]. NK-cell activity is lower
in smokers compared to nonsmokers [11] but daily intake
of LcS increases natural killer cell activity in smokers [135].
This suggests that probioticsmay be useful in COPDpatients,
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particularly those with frequent viral infections [11]. Of
interest, a diet supplemented with Lactobacillus plantarum
prevents cardiovascular disease in smokers [11].
4. Future Studies on the Effects of
Probiotics in Lung Disease
Recent studies suggest that commensal microorganisms are
not identical in their ability to affect host physiology.Ongoing
studies aimed at establishing a correlation between the
presence of particular microbes and specific diseases will
provide much needed insights into their relationships with
the immune system.The effect of microbial influences on the
immune system and specific cell types has been extensively
reviewed [136, 137]. While considerable progress has been
made in large-scale analysis of gut commensal microbiota
and its effect on the balance of pro- and anti-inflammatory
forces of the immune system, many questions remain to
be solved including which immune cells are the important
targets for probiotic actions. In the future, it will be important
to determine the mechanisms behind the probiotic action
on the respiratory tract in diseased states. This will enable a
rational approach for the use of probiotics in lung disease.
A greater knowledge of the intestinal microbiota seen in
patients with pulmonary disorders such as allergic diseases
and in healthy infants will present opportunities to select
more effective strains or combinations of strains to modulate
the immune response and treat disease. Because probiotics
modulate the composition and/or activity of the intestinal
microbiota, it is important to obtain information on the
intestinal microbiota culture, not only from fecal samples as
is commonly performed but also from those of the associated
mucosa.
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